Research-Backed Lab-Tested Peptides — Reference & Protocols
Research Dosing logoRESEARCH DOSING
Directory

Dosing Reference

Adipotide

Reconstitution volumes and example dosing schedules below. Review the Prep & Injection Guide before proceeding. Values are reference points for research workflows — verify against your own source documentation.

ADIPOTIDE: 10MG – CYCLE AND DOSING CONSIDERATIONS

28-day cycle followed by 12-28 day washout period

Daily dosing for duration of the cycle

May be dosed at any time, day or night

Adipotide does not have to be taken in a fasted state

Subcutaneous administration: abdominal region recommended

RECONSTITUTION

Mix with 2.5mL (250 units) of BAC water

DOSING PROTOCOL

Days 1-7: 8 units (.33mg), 1x/day

Days 9-14: 14 units (.55mg), 1x/day

Days 15-28: 25 units (1mg), 1x/day

Learn More

Adipotide (aka prohibitin-TP01 and fat-targeted proapoptotic peptide) is designed to selectively eliminate blood vessels feeding white adipose (fat) tissue. It combines a homing sequence that targets fat-vasculature receptors (e.g. prohibitin/annexin A2) and a pro-apoptotic (cell death-inducing) sequence that triggers vessel cell death. The mechanism aims to starve fat cells of blood supply, leading to targeted fat tissue loss rather than systemic appetite suppression. Once the fat tissue has undergone apoptosis, it is cleared by the body.

These results happen regardless of whether or not a person changes their diet or exercise regimens.

Additional Benefits

  • Targeted visceral fat reduction: Adipotide preferentially affected white adipose tissue, including visceral fat around organs. Visceral fat is linked to cardiovascular diseases, diabetes, and metabolic risk- reducing it can have outsized health benefits compared to losing general body weight.
  • Improved insulin support, for Type 2 diabetics
  • Because the targeting receptor, prohibitin, is also present in some tumor vasculature, it is of interest to cancer researchers
  • Its non-CNS peripheral action provides a mechanistic contrast to central appetite-modulating drugs

Possible Side Effects

  • Injection site reactions (redness, swelling, and/or itching)
  • Loss of appetite
  • Fatigue
  • Dizziness
  • Electrolyte imbalance
  • Dehydration
  • Dose-dependent, predictable, reversible renal injury and tubular dysfunction, including minimal to moderate tubular degeneration and necrosis after treatment, typically resolved after treatment.
  • Increased urine output and slight dehydration have been observed, potentially reflecting early kidney function disruption
  • Serum creatinine elevation indicate kidney strain, although typically mild and reversible
  • Dehydration common, potentially linked to increased diuresis and kidney changes

Interactions

  • Co-administration with other nephrotoxic agents (e.g. aminoglycosides, certain chemotherapeutics, high-dose contrast agents) could theoretically increase the risk of combined kidney toxicity.
  • Because Adipotide influences fat tissue metabolism and possibly insulin sensitivity, theoretical interactions with glucose-lowering medications (e.g. insulin or hypoglycemic agents) or lipid-modifying agents could occur, although no controlled data exist.

Contraindications

  • Do not use if pregnant or breastfeeding
  • Do not use if you have pre-existing renal impairment. Can be particularly hard on the kidneys.
Previous← ADAMAXNextAOD 9604 →

Prep & Injection Guide

Reconstitution, storage, and syringe selection.

Open Prep Guide